Alimera Sciences, Inc. (ALIM)
-NasdaqGM 4.17 
0.41(10.90%) Oct 1, 4:00PM EDT|After Hours
:
4.17 0.00 (0.00%) Oct 1, 4:51PM EDT
| Prev Close: | 3.76 |
|---|
| Open: | 3.95 |
|---|
| Bid: | N/A |
|---|
| Ask: | 4.22 x 900 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 11-Nov-13 |
|---|
| Day's Range: | 3.74 - 4.60 |
|---|
| 52wk Range: | 1.26 - 5.69 |
|---|
| Volume: | 475,097 |
|---|
| Avg Vol (3m): | 79,277 |
|---|
| Market Cap: | 131.73M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ALIMERA SCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Oct 1)
- U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN® for Chronic Diabetic Macular EdemaPR Newswire(Mon, Sep 30)
- A Closer Look At PSivida's Pipelineat Seeking Alpha(Mon, Sep 16)
- Alimera, pSivida Eye Drug Warrants FDA Approval On Third Tryat TheStreet(Wed, Aug 28)
- ALIMERA SCIENCES INC FinancialsEDGAR Online Financials(Wed, Aug 21)
- Iluvien And Tethadur: Sustained Release Treatments With Big Potential For pSividaat Seeking Alpha(Thu, Aug 15)
- ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 14)
- Alimera Sciences Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, Aug 12)
- ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhiEDGAR Online(Mon, Aug 12)
- Alimera Sciences Reports Second Quarter 2013 Financial ResultsPR Newswire(Mon, Aug 12)
- Q2 2013 Alimera Sciences Inc Earnings Release - After Market CloseCCBN(Mon, Aug 12)
- Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial ResultsPR Newswire(Mon, Aug 5)
- Keep An Eye On ICo Therapeuticsat Seeking Alpha(Mon, Jul 29)
- France's Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN®PR Newswire(Wed, Jul 24)
- pSivida announces positive opinion for reimbursement of ILUVIEN in Francetheflyonthewall.com(Wed, Jul 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 663.59 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.18 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.30 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals.
View More